CION Ameerpet
Treatment Explained · Reviewed by CION Oncologists · NABH Accredited
Hormone Therapy — The Gentler Option, Where It Fits
Most endometrial cancer is driven by oestrogen, and a tumour that responds to hormonal signals can also be treated with them. Progestin therapy supplies the hormone that opposes oestrogen, and in the right woman it can hold disease in check for a considerable time with a fraction of the toxicity of chemotherapy. It is frequently presented as a fallback for women too unwell for anything else. That framing undersells it: for low-grade, receptor-positive advanced or recurrent disease, it is a legitimate first-line choice. Whether it suits you depends on two findings from tissue you have already given.
- It works with the tumour’s biology — opposing the oestrogen signal rather than poisoning cells
- Far gentler than chemotherapy — usually tablets, no hair loss, no low blood counts
- Best in low-grade, receptor-positive disease — which is a substantial proportion of this cancer
- A first-line option, not a consolation — in the right woman it is the correct initial choice
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
How It Works
The logic runs directly from what causes this cancer in the first place.
Most endometrial cancer arises because oestrogen has stimulated the lining of the womb over years without enough progesterone to oppose it. The tumour that results frequently retains the receptors through which both hormones act — which means it is still listening.
- Progestin binds the progesterone receptor. Where the tumour expresses that receptor, the drug delivers the signal that halts proliferation — the brake the tissue never had.
- It causes maturation rather than destruction. Unlike chemotherapy, which kills dividing cells, progestin pushes tumour tissue towards a mature, non-proliferating state. That difference is why the side effect profile is so much milder.
- Receptor status predicts response. Low-grade endometrioid tumours are frequently receptor positive and respond well. High-grade and non-endometrioid tumours frequently are not, and hormone therapy has little to offer them.
- Response takes months, not weeks. Because the mechanism is tissue remodelling rather than cell killing, effects appear more slowly than with chemotherapy. That is expected rather than a sign it is not working.
For the underlying biology of why this cancer is hormone-driven in the first place, see how excess oestrogen drives endometrial cancer.
Did You Know? The single test that determines whether this option is open to you is hormone receptor status, and it is performed on tumour tissue already removed at biopsy or surgery — no new procedure is needed. Endometrial cancers that express oestrogen and progesterone receptors have retained the machinery through which hormonal signals act, and those are the tumours that respond to progestin. Low-grade endometrioid cancers are frequently receptor positive; high-grade and non-endometrioid tumours frequently are not. If you have low-grade advanced or recurrent disease and nobody has mentioned receptor status, it is a specific question worth asking by name, because it can open a considerably gentler route. Sources: NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; ESMO Clinical Practice Guidelines for endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Where It Is Used
Three quite different settings, with different intent in each.
| Setting | Role |
|---|---|
| Fertility-sparing treatment | High-dose progestin substitutes for hysterectomy in a young woman with a Grade 1 tumour confined to the lining who wants to conceive, with intensive surveillance biopsies. See fertility-sparing progestin therapy. |
| Advanced or metastatic low-grade disease | A legitimate first-line option where the tumour is low grade and receptor positive and the disease is progressing slowly. Can control disease for a considerable period. See treating advanced disease. |
| Recurrent disease | Frequently used where the recurrence is low grade and receptor positive, particularly when a woman has already had chemotherapy or wishes to defer it. See treating recurrence. |
| Where chemotherapy would be too burdensome | Age, frailty or other medical conditions may make cytotoxic treatment unwise. Progestin offers meaningful disease control without that cost — and this is a genuine indication rather than a compromise. |
| Endometrial hyperplasia | Not cancer, but the same drug class and the same mechanism, used to reverse the precancerous overgrowth. See progestin therapy for hyperplasia. |
| Not used for | High-grade or non-endometrioid disease, receptor-negative tumours, or rapidly progressing disease where a faster-acting treatment is needed. |
The framing that does women a disservice: hormone therapy is often introduced as what happens when chemotherapy is not possible. For a woman with low-grade, receptor-positive, slowly progressing disease, that is the wrong way round — it is the appropriate first choice, and reaching for chemotherapy first would expose her to greater toxicity for no clear gain. If it has been offered as a last resort, ask whether it is in fact the right first step.
Has Your Receptor Status Been Checked?
It is done on tissue already taken, and it determines whether a considerably gentler route is available to you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Gentler Treatment Is Not a Lesser One
For the right tumour, progestin is the correct first choice — not the option left when others run out.
What Taking It Is Actually Like
The contrast with chemotherapy is the point, and it is substantial.
- Usually tablets, taken at home. No day unit, no drip, no cannula. For some indications a hormone-releasing intrauterine device is used instead, delivering treatment directly to the lining.
- No hair loss and no low blood counts. Which means no neutropenic fever risk, no bone marrow monitoring before each dose, and none of the infection precautions that dominate chemotherapy.
- Monitoring is by scan and by symptoms. Rather than by blood counts. Imaging at intervals assesses whether disease is stable, shrinking or progressing.
- Treatment continues while it works. Unlike a defined number of chemotherapy cycles, hormone therapy is generally continued as long as the disease remains controlled and the treatment is tolerated — which in the right woman can be a long time.
- Most women continue ordinary life. Working, travelling, caring for family. This is the practical difference that matters most day to day.
None of which makes it side-effect free — and the side effects it does have are worth knowing about in advance rather than discovering.
Offered Chemotherapy and Wondering About a Gentler Route?
If your tumour is low grade and receptor positive, hormone therapy may be the right first choice. Worth establishing. The opinion is free.
The Side Effects It Does Have
Milder than chemotherapy, and not nothing. The first two are the commonest and the third is the one that matters most clinically.
Weight gain and increased appetite
The commonest reason women dislike this treatment, and it can be substantial with high-dose progestin. It matters more in this cancer than it would elsewhere, because excess weight is itself a driver of endometrial disease — so weight gain during treatment is a clinical issue rather than a cosmetic one and deserves active support rather than resignation. Raise it early. See weight management.
Fluid retention and bloating
Common, generally mild, and often improving after the first weeks. Swelling of the ankles and a bloated feeling are typical. Where it is marked or persistent it is worth reporting, both because it is uncomfortable and because significant fluid retention can occasionally indicate something else needing assessment.
Increased risk of blood clots
The most clinically important side effect. Progestins raise the risk of venous thromboembolism, and that risk is already elevated in women with cancer. Report new calf pain or swelling, unexplained breathlessness or chest pain urgently rather than waiting. A previous clot, or known thrombophilia, may make this treatment unsuitable and should be declared before starting.
Mood change and fatigue
Reported by a proportion of women and easily attributed to the cancer diagnosis rather than the treatment. It is worth distinguishing, because if the medication is responsible then a change of preparation or dose may resolve it. Persistent low mood is treatable in its own right and is not something to absorb silently. See emotional health after a diagnosis.
Why the Gentler Option Gets Overlooked
It requires knowing the receptor status and being willing to treat slowly. Both are worth insisting on.
MMR / MSI testing as standard
Tumour board for every diagnosis
Slides reviewed, not just the summary line
Survivorship care that is actually offered
45-minute consultations
Decisions for healing, not billing
Take The Next Step
Ask About Receptor Status by Name
It is on tissue you have already given, and it may open a route nobody has mentioned.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Hormone Therapy for Endometrial Cancer — Frequently Asked Questions
How does hormone therapy treat endometrial cancer?
By supplying the hormonal signal the tissue has been missing. Most endometrial cancer arises because oestrogen stimulated the lining of the womb over years without enough progesterone to oppose it, and the resulting tumour frequently retains the receptors through which those hormones act — meaning it is still responsive to hormonal signals. Progestin binds the progesterone receptor and halts proliferation, pushing tumour tissue towards a mature, non-dividing state rather than killing dividing cells as chemotherapy does. That difference in mechanism is precisely why the side effect profile is so much milder, and why the response develops over months rather than weeks.
Who is hormone therapy suitable for?
Principally women whose tumour is low grade, endometrioid in type, and positive for oestrogen and progesterone receptors — and this is a substantial proportion of endometrial cancer. It is used in three settings: fertility-sparing treatment of early disease in a young woman who wants to conceive; control of advanced or metastatic low-grade receptor-positive disease; and recurrent disease of the same character. It is also appropriate where chemotherapy would be too burdensome because of age, frailty or other medical conditions. It has little to offer in high-grade or non-endometrioid disease, in receptor-negative tumours, or where disease is progressing rapidly.
Is hormone therapy weaker than chemotherapy?
It is gentler, which is not the same as weaker in the situations where it applies. For a woman with low-grade, receptor-positive, slowly progressing disease, progestin can achieve durable control — sometimes for a long period — with a fraction of the toxicity of cytotoxic treatment. In that woman, reaching for chemotherapy first would mean accepting considerably greater toxicity without clear gain. It is frequently introduced as a fallback for women too unwell for anything else, and that framing does a disservice: in appropriately selected women it is a legitimate first-line choice. Where disease is high grade, receptor negative or progressing quickly, chemotherapy is the stronger option.
What are the side effects?
Considerably milder than chemotherapy, and not absent. Weight gain and increased appetite are the commonest and can be substantial with high-dose progestin — this matters more in endometrial cancer than it would elsewhere, since excess weight is itself a driver of the disease, so it deserves active support rather than resignation. Fluid retention and bloating are common and usually settle. Mood change and fatigue are reported by some women and are worth distinguishing from the effects of the diagnosis itself. The most clinically important risk is an increased chance of blood clots, which is why new calf pain or swelling, breathlessness or chest pain need urgent assessment.
How will we know if it is working?
By imaging at intervals and by how you feel, rather than by blood tests as with chemotherapy. Because the mechanism is tissue remodelling rather than cell killing, response develops over months rather than weeks, and an early scan showing stable disease is generally a good result rather than a disappointing one. Treatment is typically continued for as long as the disease remains controlled and the treatment is tolerated, rather than for a fixed number of cycles. If disease progresses, the plan changes — but a woman who has had a long period of control on a well-tolerated treatment has gained something real from it.
Medical disclaimer: This page describes progestin hormone therapy for endometrial cancer in general terms and is reviewed by a CION oncologist, following current NCCN, ESMO and ESGO–ESTRO–ESP guidance. In line with our editorial policy it describes treatment by hormone class rather than naming individual medicines. Suitability depends on tumour grade, histological type and hormone receptor status specific to you. It is not advice about your own treatment. Report new calf pain or swelling, breathlessness or chest pain urgently while taking progestin therapy.